No Data
No Data
Arcutis Biotherapeutics: Resilient Performance and Growth Potential Amidst Short-Term Fluctuations
Bears Are Losing Control Over Arcutis Biotherapeutics (ARQT), Here's Why It's a 'Buy' Now
Arcutis' ZORYVE (Roflumilast) Awarded Best Eczema Treatment by Glamour
Express News | Arcutis Biotherapeutics Inc : Guggenheim Raises Target Price to $29 From $27
Needham Maintains Arcutis Biotherapeutics(ARQT.US) With Buy Rating, Maintains Target Price $18
Morgan Stanley Maintains Arcutis Biotherapeutics(ARQT.US) With Buy Rating, Maintains Target Price $19